PRX 3140

Drug Profile

PRX 3140

Alternative Names: NTC-942; PRX-03140; PRX-3140

Latest Information Update: 10 Feb 2016

Price : $50

At a glance

  • Originator EPIX Pharmaceuticals
  • Developer Nanotherapeutics
  • Class Antidementias; Nootropics; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • No development reported Post-traumatic stress disorders

Most Recent Events

  • 09 Feb 2016 No development reported - Phase-II for Post-traumatic stress disorder (In adults) in USA (PO)
  • 21 Jan 2016 Phase-II development for Alzheimer's disease is ongoing in USA
  • 01 Jun 2013 Nanotherapeutics completes a phase II clinical trial in Post-traumatic stress disorder in USA (NCT01492699)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top